Theravance Biopharma, Inc.

Q2 2024 13F Holders

Symbol
TBPH
CUSIP
G8807B106
Type
Equity
Class
COM
Num filings
137
Total reported value, excl. options
$406 M
Manager Report Date Value ($000) Shares Option Type